Syngene Intl. (SYNGENE)

FairStock Score: 31/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I ask whether Syngene at ₹401.45 is a bargain or a hope story. Market cap is ₹16,158 Cr, P/E 72.99, P/B 3.33, and book value ₹120.41. The balance sheet looks respectable: debt/equity 0.09, Altman Z 3.20, positive FCF ₹424 Cr, and promoters hold 52.68%. Those are not signs of distress. But the earnings engine has stalled. Sales growth is -15.70%, profit growth -102.84%, and the latest quarter shows sales ₹917 Cr but net profit of only ₹15 Cr. ROE is 7.45% and ROCE 13.52%, below what I want for a high-multiple stock. The P/E of 72.99 and PEG of 19.87 are disconnected from current growth. Graham Number is ₹152.14, DCF intrinsic value ₹10.25, and margin of safety is -177.50%, meaning price is far above conservative intrinsic estimates. In other words, the market is paying a premium for a business whose profit has temporarily collapsed. The 52-week range of ₹344.85–₹678.95 shows Mr Market has already marked it down sharply, and FairStock Score of 31/100 flags risk. Piotroski F-Score 6/9 and five-year revenue CAGR 12.60% offer some comfort, but the current trend is negative, and EV/EBITDA is -2.77. Dividend yield of 0.31% gives little income support. A low-debt, cash-generating business can recover, but at this price I need evidence of profit revival and margin normalization. Until then, it’s a turnaround bet, not a Buffett-style bargain. I’d watch, not buy.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer